HAEM5:T-prolymphocytic leukaemia: Difference between revisions
| [unchecked revision] | [unchecked revision] |
mNo edit summary |
No edit summary |
||
| Line 137: | Line 137: | ||
|5 | |5 | ||
|Abnormality | |Abnormality | ||
|5p | |5p, 5q<ref>{{Cite journal|last=Tirado|first=Carlos A.|last2=Starshak|first2=Phillip|last3=Delgado|first3=Paul|last4=Rao|first4=Nagesh|date=2012-08-20|title="T-cell prolymphocytic leukemia (T-PLL), a heterogeneous disease exemplified by two cases and the important role of cytogenetics: a multidisciplinary approach"|url=https://pubmed.ncbi.nlm.nih.gov/23211026|journal=Experimental Hematology & Oncology|volume=1|issue=1|pages=21|doi=10.1186/2162-3619-1-21|issn=2162-3619|pmc=3514161|pmid=23211026}}</ref> | ||
| | | | ||
|Yes | |Yes | ||
| | |Yes | ||
| | |No | ||
|Minor diagnostic criteria | |Minor diagnostic criteria | ||
|- | |- | ||
| Line 239: | Line 239: | ||
|Yes | |Yes | ||
|Yes | |Yes | ||
|Yes | |Yes (PARP inhibitors, NCT03263637) | ||
|Deletions of or missense mutations at the | |Deletions of or missense mutations at the ''ATM'' locus are found in up to 80% to 90% of T-PLL cases. (T-PLL-ISG). | ||
|- | |- | ||
|''FBXW10'' | |''FBXW10'' | ||
| Line 267: | Line 267: | ||
|Yes | |Yes | ||
|Yes | |Yes | ||
| | | | ||
|The cumulative prevalence of these mutations in T-PLL is approximately 60%. (Dr jaffe book) | |The cumulative prevalence of these mutations in T-PLL is approximately 60%. (Dr jaffe book) | ||
|- | |- | ||
| Line 277: | Line 277: | ||
|No | |No | ||
|Yes | |Yes | ||
| | |See note | ||
| | |EZH2 inhibitors like tazemetostat have shown efficacy in other hematologic malignancies, providing a rationale for their potential use in T-PLL | ||
|- | |- | ||
|''BCOR'' | |''BCOR'' | ||
| Line 309: | Line 309: | ||
|Associated with resistance to therapy | |Associated with resistance to therapy | ||
|Mutations in TP53 are less frequent than deletions<ref>{{Cite journal|last=Stengel|first=Anna|last2=Kern|first2=Wolfgang|last3=Zenger|first3=Melanie|last4=Perglerová|first4=Karolína|last5=Schnittger|first5=Susanne|last6=Haferlach|first6=Torsten|last7=Haferlach|first7=Claudia|date=2016-01|title=Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker|url=https://pubmed.ncbi.nlm.nih.gov/26493028|journal=Genes, Chromosomes & Cancer|volume=55|issue=1|pages=82–94|doi=10.1002/gcc.22313|issn=1098-2264|pmid=26493028}}</ref> | |Mutations in TP53 are less frequent than deletions<ref>{{Cite journal|last=Stengel|first=Anna|last2=Kern|first2=Wolfgang|last3=Zenger|first3=Melanie|last4=Perglerová|first4=Karolína|last5=Schnittger|first5=Susanne|last6=Haferlach|first6=Torsten|last7=Haferlach|first7=Claudia|date=2016-01|title=Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker|url=https://pubmed.ncbi.nlm.nih.gov/26493028|journal=Genes, Chromosomes & Cancer|volume=55|issue=1|pages=82–94|doi=10.1002/gcc.22313|issn=1098-2264|pmid=26493028}}</ref> | ||
|- | |||
|SAMHD1 | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|}Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content. | |}Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content. | ||
==Epigenomic Alterations== | ==Epigenomic Alterations== | ||